NCCN Annual Conference | Conference

TKIs Dominate NCCN Update in EGFR+ NSCLC

April 2nd 2016

Testing for EGFR mutations should be routine in patients with non–small cell lung cancer. With the presence of an EGFR mutation TKIs are an appropriate treatment option across multiple lines of therapy, according to the latest update from the NCCN.

Optimizing Current Treatments for CLL as New Agents Are Investigated

April 2nd 2016

Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.

NCCN Broadens Myeloma Diagnostic Criteria, Recommends Novel Agents

April 2nd 2016

The updated NCCN myeloma guideline broadens the diagnostic criteria for active disease and integrates novel therapies into the treatment paradigm.

Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines

April 2nd 2016

Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.

Dr. Anderson on How the Definition of Myeloma Has Changed

April 2nd 2016

Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how the definition of myeloma has changed.

NCCN Readies Practitioners for Tapping the Potential of Biosimilars

April 1st 2016

While biosimilars have the potential to create competition and result in healthcare savings, the path to the marketplace has proven complex.

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

April 1st 2016

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

NCCN Guideline Expands Locoregional Treatment Candidates in HCC

April 1st 2016

Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma.

Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines

April 1st 2016

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.

NCCN's Evidence Blocks Make the Best of Imprecise Drug Data

March 31st 2016

The NCCN's Evidence Blocks need further data and refinement to overcome subtleties of distinction in drug performance, but they’re the best value system developed so far, NCCN officials reported at their 2016 Annual Conference.

Dr. Zelenetz on the Role of Biosimilars in Cancer Care

March 31st 2016

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC

March 31st 2016

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

The Many Facets of Palliative Care Call for Team-Based Approach

March 31st 2016

The 2016 NCCN Annual Conference included a push to find more effective ways to encourage and deliver palliative care services across a variety of settings in oncology.

“Forgotten Lessons” May Help Advance Colorectal Cancer Care

March 31st 2016

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

NEXT PAGE
PREVIOUS PAGE